Overview

Xeomin® and Gait Related Mobility After Stroke

Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The aim of the present pilot study is to evaluate the association between change in gait related mobility in ambulatory male and female adult hemiparetic patients before and 4-6-weeks after Xeomin® injection into the upper limb, using two standardized tests of physical function in outpatient rehabilitation that are widely used; the 10-meter walk test and the timed 'up and go' test (TUG).
Phase:
Phase 4
Details
Lead Sponsor:
Atrium Health
Collaborator:
Merz Pharmaceuticals GmbH
Treatments:
incobotulinumtoxinA